Wednesday, November 17, 2021 12:36:20 PM
I appreciate your comments because many on this board feel as you do but Linda has a strategy and she is in control not us. Even the SEC basically agrees or we would have seen additional actions so..
I am well aware of who is in control and I have a big problem with her strategy, even if she thinks what she is doing is for the benefit of shareholders. Again, what she is doing has never been done before by a public biotech. There are multiple reasons that public biotechs release TLD pretty much as soon as they receive it. One of those reasons is that it is hard to satisfy the requirements of the securities laws and regulations if you decide to withhold material information that directly affects the future of your company for more than a year.
As for the SEC...they don't actively monitor every public company. They will review a company's disclosures every couple years and issue a comment letter that will ask for explanations of various things, but unless they receive a complaint or a disclosure triggers something they are monitoring for all public companies, then they won't know what is happening. If someone really made a complaint in this case, then depending on who the person is and how the complaint was communicated (and what information was provided), the SEC will definitely take it seriously and will start looking into it quickly, especially if the complaint made it clear that the company is directing the exercise of "in the money" warrants as they sit on the results of their Phase III trial.
I am definitely not buying any more shares.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
